JPH0160469B2 - - Google Patents
Info
- Publication number
- JPH0160469B2 JPH0160469B2 JP24819284A JP24819284A JPH0160469B2 JP H0160469 B2 JPH0160469 B2 JP H0160469B2 JP 24819284 A JP24819284 A JP 24819284A JP 24819284 A JP24819284 A JP 24819284A JP H0160469 B2 JPH0160469 B2 JP H0160469B2
- Authority
- JP
- Japan
- Prior art keywords
- amount
- cotinine
- oxide
- solvent
- nicotine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 33
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 claims description 6
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 claims description 6
- 229950006073 cotinine Drugs 0.000 claims description 6
- CIPULDKLIIVIER-VIFPVBQESA-N cotinine N-oxide Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN(=O)=C1 CIPULDKLIIVIER-VIFPVBQESA-N 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 150000004965 peroxy acids Chemical class 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 7
- 229960002715 nicotine Drugs 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 235000002597 Solanum melongena Nutrition 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-SNVBAGLBSA-N (+)-nicotine Chemical compound CN1CCC[C@@H]1C1=CC=CN=C1 SNICXCGAKADSCV-SNVBAGLBSA-N 0.000 description 1
- 229930182841 (R)-nicotine Natural products 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical group CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RCTFHBWTYQOVGJ-UHFFFAOYSA-N chloroform;dichloromethane Chemical compound ClCCl.ClC(Cl)Cl RCTFHBWTYQOVGJ-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は新規かつ有用な4―アミノニコチン及
び、その製造方法に関するものである。DETAILED DESCRIPTION OF THE INVENTION (Field of Industrial Application) The present invention relates to a new and useful 4-aminonicotine and a method for producing the same.
(従来の技術)
近年、人工抗原の研究は人体あるいは薬物によ
る治療など医学的、及び生物学的研究分野におい
て盛んに行なわれており、たとえば、インシユリ
ン、モルフイン、LSDなどの人工抗原が実際に
合成され、これらが研究の進展に大きく寄与して
いることは周知のことである。ニコチンについて
も喫煙医学的見地から、これが人体に及ぼす影響
について長年にわたり研究が続けられており、こ
れらの人工抗原も合成され、これが微量ニコチン
の放射免疫定量への応用についても実際に行なわ
れている。(Prior Art) In recent years, research on artificial antigens has been actively conducted in the medical and biological research fields, such as treatment with the human body or drugs. It is well known that these methods greatly contribute to the progress of research. Regarding nicotine, research has continued for many years on its effects on the human body from the medical perspective of smoking, and these artificial antigens have also been synthesized, and their application to radioimmunoquantification of trace amounts of nicotine is also being carried out. .
(発明が解決しようとする問題点)
しかし、天然の葉たばこ中に存在するニコチン
はすべて1体で存在しているので、通常必要とさ
れる人工抗原の抗体は1体のみに特異的に反応す
るものが望ましいが、従来の人工抗原の合成方法
の多くは、その合成過程においてラセミ化を起こ
してしまう。そのため、通常必要とされる人工抗
原の1体抗体産出能力を半減してしまう欠点があ
つた。この欠点を改善したニコチン誘導体として
本発明の化合物に類似した光学活性なニコチン誘
導体が提案されている(特公、昭54―914)。しか
し、このニコチン誘導体は、単離精製が煩雑であ
り、また極めて吸湿性の高い化合物であるため、
保管や取り扱いが不便である。(Problem to be solved by the invention) However, since all the nicotine that exists in natural leaf tobacco exists in one form, the normally required artificial antigen antibody reacts specifically to only one form. However, many conventional methods for synthesizing artificial antigens result in racemization during the synthesis process. Therefore, the drawback was that the normally required single-body antibody production ability of artificial antigens was halved. An optically active nicotine derivative similar to the compound of the present invention has been proposed as a nicotine derivative that improves this drawback (Japanese Patent Publication, 1982-914). However, this nicotine derivative is complicated to isolate and purify, and is an extremely hygroscopic compound.
Storage and handling are inconvenient.
本発明は、このような従来の公知のニコチン誘
導体に伴なう欠点がなく、合成方法及び単離方法
が極めて容易で、かつ、光学純度を保つたまま製
造しうるニコチン誘導体を提供することを目的と
したものである。 The present invention aims to provide a nicotine derivative that does not have the drawbacks associated with conventionally known nicotine derivatives, can be synthesized and isolated by extremely easy methods, and can be produced while maintaining optical purity. This is the purpose.
(問題点を解決するための手段)
すなわち、本発明は次式に示す4―アミノニコ
チン及び、その製造方法である。(Means for Solving the Problems) That is, the present invention is 4-aminonicotine represented by the following formula and a method for producing the same.
本化合物は、文献未載の新規化合物であり、以
下にその物性値を示す。 This compound is a new compound that has not been published in any literature, and its physical properties are shown below.
4―アミノニコチン
性状;白色結晶
融点;125〜126℃1
H NMR(溶媒CDCL3,内部標準TMS);
(ppm)
1.86(m,2H),1.98(m,1H),2.02(m,1H),
2.18(s,3H),2.22(t,J=8.7Hz,1H),
3.12(t,J=8.7Hz,1H),3.16(t,J=9.4
Hz,1H),5.60(bs,2H),6.41(d,J=5.4
Hz,1H),8.00(s,1H),8.07(d,J=5.4
Hz,1H)
C NMR(溶媒CDCL3、内部標準TMS);
(ppm)
22.61(t),30.15(t),40.09(q),56.58(t)
,
70.00(d),110.09(d),119.27(s),148.86
(d),149.83(d),152.45(s)
MASS;(M/Z)
177(M+;22),84(54),119(14),121(42),
134(20),148(40),162(100),176(11)
旋光度;〔α〕25 d=−95.2゜(c=0.7,MeOH)
4―アミノニコチンは、コチニンを過酸で酸化
してコチニン―N―オキシドとした後、濃硫酸、
発煙硝酸でニトロ化し、酢酸中、鉄で還元した
後、ジボランで還元することにより容易に得るこ
とができる。以下に、その製造方法を後述の製造
例にもとづいて詳細に説明する。 4-Aminicotine properties; white crystal melting point; 125-126°C 1H NMR (solvent CDCL 3 , internal standard TMS);
(ppm) 1.86 (m, 2H), 1.98 (m, 1H), 2.02 (m, 1H),
2.18 (s, 3H), 2.22 (t, J=8.7Hz, 1H),
3.12 (t, J = 8.7Hz, 1H), 3.16 (t, J = 9.4
Hz, 1H), 5.60 (bs, 2H), 6.41 (d, J = 5.4
Hz, 1H), 8.00 (s, 1H), 8.07 (d, J=5.4
Hz, 1H) C NMR (solvent CDCL 3 , internal standard TMS);
(ppm) 22.61 (t), 30.15 (t), 40.09 (q), 56.58 (t)
,
70.00(d), 110.09(d), 119.27(s), 148.86
(d), 149.83 (d), 152.45 (s) MASS; (M/Z) 177 (M+; 22), 84 (54), 119 (14), 121 (42),
134 (20), 148 (40), 162 (100), 176 (11) Optical rotation; [α] 25 d = -95.2° (c = 0.7, MeOH) 4-Aminonicotine oxidizes cotinine with peracid After converting to cotinine-N-oxide, concentrated sulfuric acid,
It can be easily obtained by nitration with fuming nitric acid, reduction with iron in acetic acid, and subsequent reduction with diborane. The manufacturing method will be described in detail below based on manufacturing examples described later.
コチニンを、コチニンに対し2〜5倍量、望ま
しくは3倍量の酢酸に溶解させ、酢酸に対し0.2
倍量の30%過酸化水素水を加え、70℃で1〜10時
間、望ましくは5時間反応させる。反応後減圧下
溶媒を留去させ、エチルアルコール、メチルアル
コール等のアルコールを適当量加え、過剰の過酸
化水素を分解させ、水を加え減圧下溶媒を留去さ
せる。得られた油状物質に炭酸カリウム、炭酸ナ
トリウム等のアルカリを加え中和させ、クロロフ
オルム、ジクロロメタン等の有機溶媒で抽出し、
硫酸ナトリウム、硫酸マグネシウム等で乾燥さ
せ、減圧下溶媒を留去させると、コチニン―N―
オキシドが収率95〜99%で白色結晶として得られ
る。 Cotinine is dissolved in 2 to 5 times the amount of cotinine, preferably 3 times the amount of acetic acid, and 0.2 times the amount of cotinine is dissolved in acetic acid.
Add twice the amount of 30% hydrogen peroxide solution and react at 70°C for 1 to 10 hours, preferably 5 hours. After the reaction, the solvent is distilled off under reduced pressure, an appropriate amount of alcohol such as ethyl alcohol or methyl alcohol is added to decompose excess hydrogen peroxide, water is added, and the solvent is distilled off under reduced pressure. The obtained oily substance is neutralized by adding an alkali such as potassium carbonate or sodium carbonate, and extracted with an organic solvent such as chloroform or dichloromethane.
After drying with sodium sulfate, magnesium sulfate, etc. and distilling off the solvent under reduced pressure, cotinine-N-
The oxide is obtained as white crystals with a yield of 95-99%.
得られたコチニン―N―オキシドを、それに対
し10〜20倍量、望ましくは12倍量の濃硫酸及び同
量の発煙硝酸に溶解させ、130℃で3〜10時間、
望ましくは5時間反応させる。反応後、反応液
を、加えた濃硫酸の2倍量程度の氷に注意深く注
ぐ。次に、炭酸カリウム、炭酸ナトリウム等のア
ルカリを加え中和し、クロロフオルム、ジクロロ
メタン等の有機溶媒で抽出する。抽出液を硫酸ナ
トリウム、硫酸マグネシウム等で乾燥させた後、
減圧下溶媒を留去し、少量のクロロフオルムで再
結晶させると、4―ニトロコチニン―N―オキシ
ドが収率30〜45%で薄黄色の結晶として得られ
る。 The obtained cotinine-N-oxide was dissolved in 10 to 20 times its amount, preferably 12 times its amount, of concentrated sulfuric acid and the same amount of fuming nitric acid, and then heated at 130°C for 3 to 10 hours.
Preferably, the reaction is allowed to proceed for 5 hours. After the reaction, carefully pour the reaction solution onto ice with an amount twice as much as the amount of concentrated sulfuric acid added. Next, an alkali such as potassium carbonate or sodium carbonate is added to neutralize the mixture, and the mixture is extracted with an organic solvent such as chloroform or dichloromethane. After drying the extract with sodium sulfate, magnesium sulfate, etc.
The solvent is distilled off under reduced pressure and recrystallized from a small amount of chloroform to obtain 4-nitrocotinine-N-oxide as pale yellow crystals in a yield of 30-45%.
得られた4―ニトロコチニン―N―オキシド
を、それに対し5〜20倍量、望ましくは8倍量の
酢酸に溶解させ、4―ニトロコチニン―N―オキ
シドに対し1〜3倍量、望ましくは2倍量の鉄粉
を加え、2〜10時間、望ましくは3時間酢酸の沸
点で還流させる。反応後、未反応の鉄粉をろ過
し、減圧下酢酸を留去した後、炭酸カリウム、炭
酸ナトリウム等のアルカリで中和し、クロロフオ
ルムジクロロメタン等の有機溶媒で抽出し、硫酸
ナトリウム、硫酸マグネシウム等で乾燥させ、減
圧下溶媒を留去させた後、少量のクロロフオルム
で再結晶させると、4―アミノコチニンが収率40
〜65%で白色結晶として得られる。次に、得られ
た4―アミノコチニンと、それに対し4〜8倍
量、望ましくは5倍量の水素化ホウ素ナトリウム
を、4―アミノコチニンに対し8〜20倍量、望し
くは、10倍量のジグリムに溶解し、水素化ホウ素
ナトリウムに対し1.25倍量の3フツ化ホウ素・エ
ーテル錯体をゆつくり滴下する。滴下後、室温
で、3〜5時間、望ましくは4時間撹拌させる。
その後、はじめに加えた4―アミノコチニンに対
し5〜20倍量、望ましくは10倍量の10%塩酸に反
応液を注ぎ、炭酸カリウム、水酸化ナトリウム等
のアルカリで中和し、はじめに加えた4―アミノ
コチニンに対し30倍量のクロロフオルムで抽出す
る。減圧下溶媒を留去すると、4―アミノニコチ
ンが白色結晶として収率50〜70%で得ることがで
きる。 The obtained 4-nitrocotinine-N-oxide is dissolved in 5 to 20 times the amount of acetic acid, preferably 8 times the amount of 4-nitrocotinine-N-oxide. Add twice the amount of iron powder and reflux at the boiling point of acetic acid for 2 to 10 hours, preferably 3 hours. After the reaction, unreacted iron powder is filtered, acetic acid is distilled off under reduced pressure, neutralized with an alkali such as potassium carbonate or sodium carbonate, extracted with an organic solvent such as chloroform dichloromethane, and extracted with sodium sulfate or magnesium sulfate. 4-aminocotinine was obtained in a yield of 40.
Obtained as white crystals at ~65%. Next, the obtained 4-aminocotinine and sodium borohydride in an amount 4 to 8 times, preferably 5 times the amount of 4-aminocotinine, are added in an amount of 8 to 20 times, preferably 10 times the amount of 4-aminocotinine. of the boron trifluoride/ether complex is slowly added dropwise to the solution in an amount of 1.25 times the amount of sodium borohydride. After dropping, the mixture is stirred at room temperature for 3 to 5 hours, preferably 4 hours.
Thereafter, the reaction solution was poured into 10% hydrochloric acid in an amount of 5 to 20 times, preferably 10 times, the amount of 4-aminocotinine added at the beginning, and neutralized with an alkali such as potassium carbonate or sodium hydroxide. - Extract with 30 times the amount of chloroform compared to aminocotinine. When the solvent is distilled off under reduced pressure, 4-aminonicotine can be obtained as white crystals in a yield of 50 to 70%.
以上詳細に説明したように、本発明による製造
方法は、アミノ基が位置選択的に4位に導入で
き、さらに光学純度を失なうことなく製造するこ
とができることから、後で述べるように、ニコチ
ンの人工抗原として極めて重要な特徴である、ピ
リジン環、ピロリジン環、さらに光学活性を維持
しているという利点がある。 As explained in detail above, the production method according to the present invention allows the amino group to be introduced into the 4-position regioselectively, and can be produced without losing optical purity. It has the advantage of maintaining the pyridine ring and pyrrolidine ring, which are extremely important features for an artificial nicotine antigen, as well as optical activity.
(実施例)
100mlナスフラスコ中、3.4g(20mmol)のコ
チニンを、12mlの酢酸に溶解させ、その溶液中に
30%過酸化水素2.4mlを加え70℃で5時間反応さ
せる。反応後、減圧下酢酸を留去しエチルアルコ
ールを加え過剰の過酸化水素を処理し、水を加え
減圧下溶媒を留去し、炭酸カリウムで中和し、ク
ロロフオルムで抽出し硫酸ナトリウムで乾燥させ
溶媒を留去し、コチニン―N―オキシドを白色結
晶として3.7g(収率98%)得た。(Example) In a 100 ml eggplant flask, 3.4 g (20 mmol) of cotinine was dissolved in 12 ml of acetic acid.
Add 2.4 ml of 30% hydrogen peroxide and react at 70°C for 5 hours. After the reaction, acetic acid was distilled off under reduced pressure, ethyl alcohol was added to remove excess hydrogen peroxide, water was added and the solvent was distilled off under reduced pressure, neutralized with potassium carbonate, extracted with chloroform, and dried over sodium sulfate. The solvent was distilled off to obtain 3.7 g (yield 98%) of cotinine-N-oxide as white crystals.
得られたコチニン―N―オキシド3.7g
(19mmol)を100mlナスフラスコ中、濃硫酸40
ml、発煙硝酸40mlに溶解させ130℃で5時間反応
させる。反応後、反応液を100mlの氷に注ぎ炭酸
カリウムで中和し、クロロフオルムで抽出し硫酸
ナトリウムで乾燥させ溶媒を留去した後、少量の
クロロフオルムで再結晶させ、4―ニトロコチニ
ン―N―オキシドを薄黄色の針状結晶として1.8
g(収率40%)得た。 3.7 g of cotinine-N-oxide obtained
(19 mmol) in a 100 ml eggplant flask, concentrated sulfuric acid 40
ml, dissolved in 40 ml of fuming nitric acid and reacted at 130°C for 5 hours. After the reaction, the reaction solution was poured into 100 ml of ice, neutralized with potassium carbonate, extracted with chloroform, dried over sodium sulfate, the solvent was distilled off, recrystallized with a small amount of chloroform, and 4-nitrocotinine-N-oxide was obtained. 1.8 as light yellow needle-shaped crystals
g (yield 40%) was obtained.
得られた4―ニトロコチニン―N―オキシド
1.8g(7.6mmol)を100mlナスフラスコ中、酢酸
20mlに溶解させ、鉄粉4gを加え3時間還流させ
る。反応後、未反応の鉄粉をろ過し、減圧下酢酸
を留去した後、炭酸カリウムで中和し、水酸化鉄
をろ別し、クロロフオルムで抽出し、硫酸ナトリ
ウムで乾燥させ、溶媒を減圧下留去した後、少量
のクロロフオルムで再結晶させ、4―アミノコチ
ニンを1.0g(収率62%)得た。 Obtained 4-nitrocotinine-N-oxide
1.8g (7.6mmol) of acetic acid in a 100ml eggplant flask
Dissolve in 20 ml, add 4 g of iron powder, and reflux for 3 hours. After the reaction, unreacted iron powder is filtered, acetic acid is distilled off under reduced pressure, neutralized with potassium carbonate, iron hydroxide is filtered off, extracted with chloroform, dried over sodium sulfate, and the solvent is removed under reduced pressure. After evaporation, the residue was recrystallized from a small amount of chloroform to obtain 1.0 g (yield: 62%) of 4-aminocotinine.
得られた4―アミノコチニニ1.9g(10mmol)
と水素化ホウ素ナトリウム1.9g(50mmol)を、
50mlナスフラスコ中、ジグリム20mlに溶解させ、
BF3・Et2O8.8g(63mmol)を滴下させる。滴下
後、室温で4時間撹拌させた後、10%塩酸20ml中
に注ぎ、次いで水酸化ナトリウムで中和し、クロ
ロフオルムで抽出する。硫酸ナトリウムで乾燥さ
せた後、溶媒を減圧下留去し減圧蒸留にかけ、
160℃(2mmHg)留分として4―アミノニコチン
を1.0g(収率56%)得た。 Obtained 4-aminocochinini 1.9g (10mmol)
and 1.9 g (50 mmol) of sodium borohydride,
Dissolve in 20ml of diglyme in a 50ml eggplant flask,
8.8 g (63 mmol) of BF 3 .Et 2 O is added dropwise. After the dropwise addition, the mixture was stirred at room temperature for 4 hours, poured into 20 ml of 10% hydrochloric acid, neutralized with sodium hydroxide, and extracted with chloroform. After drying with sodium sulfate, the solvent was distilled off under reduced pressure and subjected to vacuum distillation.
1.0 g (yield: 56%) of 4-aminonicotine was obtained as a 160°C (2 mmHg) fraction.
(発明の効果)
4―アミノニコチンは上述したように、カルボ
キシル基を有する蛋白質などの高分子化合物とペ
プチド合成試薬を用いて結合させることにより、
ニコチンの人工抗原として利用することができ、
これらの人工抗原は高い抗体価の抗体を産出せし
める能力がある。すなわち、本発明の化合物の構
造式から明らかなように、これらの人工抗原は本
発明化合物の一級アミノ基において高分子化合物
と結合しているので、ニコチンの構造、特にその
特徴であるピリジン環、N―メチルピロリジン環
になんらの変化を加えることなく、特異性の高い
抗体を産出せしめる一因となつている。(Effect of the invention) As mentioned above, 4-aminonicotine can be produced by bonding it to a polymer compound such as a protein having a carboxyl group using a peptide synthesis reagent.
Can be used as an artificial antigen for nicotine,
These artificial antigens have the ability to produce antibodies with high titers. That is, as is clear from the structural formula of the compound of the present invention, these artificial antigens are bonded to a polymer compound at the primary amino group of the compound of the present invention. This contributes to the production of highly specific antibodies without making any changes to the N-methylpyrrolidine ring.
さらに、本発明化合物より得られた人工抗原が
動物体内に産出させる抗体は―ニコチンに対し
て特異的に反応し、d―ニコチンとの交叉反応が
小さいなど従来知られているニコチンの人工抗原
に比し極めてすぐれた利点がある。 Furthermore, the antibodies produced in the animal body by the artificial antigen obtained from the compound of the present invention react specifically with nicotine and have a small cross-reactivity with d-nicotine, which is similar to the previously known artificial antigen of nicotine. There are significant advantages compared to this.
Claims (1)
シドとした後濃硫酸、発煙硝酸と反応させ、4―
ニトロコチニン―N―オキシドとし、酢酸中、鉄
で還元した後、ジボランで還元することを特徴と
する4―アミノニコチンの製造方法。[Claims] 4-aminonicotine represented by the linear formula 2 Cotinine is treated with peracid to form cotinine-N-oxide, and then reacted with concentrated sulfuric acid and fuming nitric acid to form 4-
A method for producing 4-aminonicotine, which comprises preparing nitrocotinine-N-oxide, reducing it with iron in acetic acid, and then reducing it with diborane.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP24819284A JPS61126084A (en) | 1984-11-26 | 1984-11-26 | 4-aminocotinine and production thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP24819284A JPS61126084A (en) | 1984-11-26 | 1984-11-26 | 4-aminocotinine and production thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS61126084A JPS61126084A (en) | 1986-06-13 |
JPH0160469B2 true JPH0160469B2 (en) | 1989-12-22 |
Family
ID=17174570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP24819284A Granted JPS61126084A (en) | 1984-11-26 | 1984-11-26 | 4-aminocotinine and production thereof |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS61126084A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5164504A (en) * | 1991-01-16 | 1992-11-17 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for immunoassays for cotinine derivatives |
-
1984
- 1984-11-26 JP JP24819284A patent/JPS61126084A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS61126084A (en) | 1986-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101855611B1 (en) | Process for the preparation of (r,s)-nicotine | |
CA1340549C (en) | Method of preparing sphingosine derivatives | |
JPH0776209B2 (en) | Process for producing optically active 3-hydroxypyrrolidine derivative | |
KR20050050145A (en) | Method for the synthesis of a benzimidazole compound | |
JPH0160469B2 (en) | ||
JP2006519786A (en) | Chemical methods for making intermediates to obtain N-formylhydroxylamine compounds | |
JPH0160468B2 (en) | ||
US11708320B2 (en) | Environmentally-friendly hydroazidation of olefins | |
US5446166A (en) | Preparation of pyrrol and oxazole compounds: formation of porphyrins and C-acyl-α-amino acid esters therefrom | |
KR100625649B1 (en) | The method of preparing ?-hydroxybutyric acid alkyl esters | |
JP6233934B2 (en) | Process for producing desmosine, isodesmosine, and derivatives thereof | |
KR101009467B1 (en) | Taxan derivative useful for synthesizing docetaxel and a method for preparing the same | |
JP2011105691A (en) | Method for producing trifluoromethylcyclopropane compound | |
JP2012036161A (en) | Method for producing optically active trifluoromethylcyclopropane compound | |
JP2558491B2 (en) | Organothiomethylation of α, β-unsaturated carbonyl compounds | |
JP3272170B2 (en) | Method for producing pyridine derivative | |
JP3274011B2 (en) | Cyclopentaquinoline derivative | |
JP2571939B2 (en) | Cyclopentenone derivatives and their production | |
KR20120055562A (en) | Method for producing pyrazole glycoside derivatives | |
FR2777278A1 (en) | Production of 3-hydroxymethyl-quinuclidine useful as intermediate for antihistamine mequitazine | |
JPS58216185A (en) | Nicotine derivative | |
JP2004250364A (en) | Method for producing imidazole-4,5-dicarboxylic acid | |
JPS6111231B2 (en) | ||
WO1991003455A1 (en) | Process for making succinyl acetone | |
JPH0477752B2 (en) |